Abstracts tagged "autoimmune diseases"

Abstract Number: 2605 • ACR Convergence 2025
Do Patients Recall Their Rheumatic Diagnoses Accurately? A Comparison by Disease Type
Sydney Liles¹, Samantha Namit², Jennifer Copson³, Matthew Librizzi², Sophia Baionno², Nurten Gizem Tore², Yvonne Lee⁴ and Daniel K. White¹, ¹University of Delaware, Newark, DE, ²University of Delaware, Newark, ³University of Delaware, Wilmington, DE, ⁴Northwestern University, Chicago, IL
Background/Purpose: Rheumatic diseases represent a major public health concern in the United States due to their high prevalence and their association with disability. Observational studies…
Abstract Number: 2525 • ACR Convergence 2025
Point-of-Care Risk Factors for Systemic Disease in Patients Presenting with Small Vessel Vasculitis of the Skin
Arjun Mahajan¹, William Song², Andrew Walls³, Arash Mostaghimi³, Robert Micheletti² and Evan Piette³, ¹Harvard Medical School, Boston, ²Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ³Brigham and Women's Hospital, Harvard Medical School, Boston
Background/Purpose: Small vessel vasculitis (SVV) presenting in the skin may be skin-limited or a manifestation of systemic vasculitis or an underlying autoimmune disease. However, no…
Abstract Number: 2398 • ACR Convergence 2025
Analytical performance of the HEp-2 substrate Diagnostic Kit for ANA as an initial step in the evaluation of a novel Fully Automated IFA Analyzer in a laboratory in England
Jason Sillitoe¹, Ewa Fiorentino-Rozek², Gerber Gomez³, Christian Fischer³ and Caroline Wilson¹, ¹North East Innovation Lab, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, ²Clinical Affairs, AliveDx Suisse SA, Eysins, Vaud, Switzerland, ³Scientific & Medical Affairs, AliveDx Suisse SA, Eysins, Switzerland
Background/Purpose: Indirect immunofluorescence assay (IFA) on HEp-2 cells (HEp-2 IFA) remains a key tool in the diagnostic work-up of autoimmune connective tissue diseases (CTD). Traditionally…
Abstract Number: 2030 • ACR Convergence 2025
Krebs von den Lungen 6 levels (∆KL6) is a reliable marker of disease activity and response to therapy in CTD-ILD
fredeswinda Romero-Bueno¹, lydia Abasolo Alcazar², Mª Jesus Rodriguez-Nieto³, Cristina Vadillo Font⁴, Maria asuncion Nieto⁴, Laura Cebrian⁵, Belen Lopez Muñiz⁶, Jesus Loarce Martos⁷, Juan A Rigual⁷, Hilda Godoy Tundidor⁸, Rosalia Laporta⁹, Irene Llorente Cubas¹⁰, Gema Bonilla¹¹, Luis Gomez Carrera¹², Rosario Garcia Vicuña¹³, Ana Jaureguizar⁷, Jose Luis Morell Hita⁷, Claudia Valenzuela¹⁰ and Olga Sanchez Pernaute¹⁴, ¹University Hospital Fundación Jiménez Díaz"", Madrid, Spain, ²IdISSC. HCSC, Madrid, Madrid, Spain, ³Fundacion Jimenez Diaz (IIS-HUFJD), Madrid, Spain, ⁴Hospital Clínico S Carlos, Madrid, Spain, ⁵Department of Rheumatology, Hospital Universitario Infanta Leonor / Universidad Complutense de Madrid, Madrid, Spain, Madrid, Spain, ⁶Hospital Universitario Infanta Leonor, Madrid, Spain, ⁷Hospital Ramón y Cajal, Madrid, Spain, ⁸Hospital Universitario puerta de hierro, Madrid, Spain, ⁹Hospital Puerta de Hierro Majadahonda, Madrid, Spain, ¹⁰Hospital Universitario Princesa, Madrid, Spain, ¹¹Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, ¹²Hospital Universitario La Paz, Madrid, Spain, ¹³Hospital Universitario de la Princesa, Madrid, Spain, ¹⁴Clinica Universidad de Navarra, Madrid, Madrid, Spain
Background/Purpose: Krebs von den Lungen-6 (KL6) is produced by type 2 alveolar epithelial cells. High circulating KL6 levels show a good accuracy in the diagnosis…
Abstract Number: 1861 • ACR Convergence 2025
Accelerated and Gene-Specific Patterns of Clonal Hematopoiesis Distinguish Subtypes of Systemic Sclerosis
Brecca Miller¹, Shervin Assassi², Maureen Mayes³, alejandro Molina⁴, Kelly Ruggles⁵, David Beck⁶ and Meng Zhang⁷, ¹Center for Human Genetics and Genomics, NYU Grossman School of Medicine, Brooklyn, NY, ²Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ³UT Health Houston Division of Rheumatology, Houston, TX, ⁴Georgia Institute of Technology, Atlanta, GA, ⁵NYU Grossman School of Medicine, Brooklyn, NY, ⁶Center for Human Genetics and Genomics, NYU Grossman School of Medicine. Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine. Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA, New York, NY, ⁷UTHealth Houston Division of Rheumatology, Houston
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by widespread fibrosis, vasculopathy, autoantibody presence, and high mortality in its diffuse subtype with limited effective…
Abstract Number: 1697 • ACR Convergence 2025
Dynamic Effects of T cell Engager Therapy on B and T cells in Autoimmune Disease.
Laura Bucci¹, Tobias Rothe², Ann-Kathrin Goetz³, Kirill Anoshkin¹, Danae-Mona Nöthling¹, Melanie Hagen¹, Sebastian Böltz¹, Andreas Wirsching¹, Georg Schett⁴ and Ricardo Grieshaber-Bouyer⁵, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlagen, Germany, ³Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, ⁴Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁵University Hospital Erlangen, Erlangen, Germany
Background/Purpose: Treatment of autoimmune disease with T cell engagers (TCEs) leads to profound peripheral B cell depletion, followed by their reconstitution. However, the dynamics of…
Abstract Number: 1544 • ACR Convergence 2025
Voclosporin in Lupus Nephritis: Meta-Analysis of 6-Month and 1-Year Efficacy with 1-Year Safety Outcomes
Sri Laxmi Priya Sunkara¹, Ravi Medarametla², Megha Kotha³ and Wael Jarjour⁴, ¹White river medical center, batesville, AR, ²Mamata Medical College, Guntur, Andhra Pradesh, India, ³Ohio State University, Columbus, OH, ⁴The Ohio State University, Columbus, OH
Background/Purpose: Lupus nephritis (LN), is the most sever organ manifestation of systemic lupus erythematosus (SLE) and it contributes significantly to morbidity and mortality. . Standard…
Abstract Number: 1394 • ACR Convergence 2025
Burden of Comorbidities Across EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) Domains: Treatment Prevalence Among Commercially Insured Sjögren’s Patients in the United States
Minoti Ganguli, Annie Kilby, Ahva Shahabi and Tsu-Chieh Jay Lin, Amgen Inc., Thousand Oaks, CA
Background/Purpose: Sjögren’s disease (SjD) is a systemic disorder characterized by exocrine gland inflammation, leading to dry eyes/mouth, and multiple organ systems involvement1. The European League…
Abstract Number: 1210 • ACR Convergence 2025
Artificial Intelligence-Based Capillaroscopy and Laboratory Biomarkers to Predict Disease Activity in Idiopathic Inflammatory Myopathies: Preliminary Data from the CapIAMI Cohort
Gema María Lledó Ibáñez¹, Jorge Álvarez-Troncoso², Borja del Carmelo Gracia Tello³, Sergio Prieto-Gonzalez⁴, Elena Martínez Robles⁵, Diana Cristina-Varela⁶, Sebastián Molina-Ríos⁷, Luis Sáez Comet⁸, Eiman Soliman⁹, Franklin Uguña¹⁰, Miguel Antonio Mesa¹¹, Miguel Martín Cascón¹², Tânia Santiago¹³, Grace-Jimena Santamaría-Peñaloza¹⁴, Tsvetoslav Georgiev¹⁵, Santiago Bernal-Macias¹⁶, Begoña Marí-Alfonso¹⁷, Jesus Ballano Rodríguez-Solís¹⁸, Sally Patricia Pino Hernández¹⁹, Jacek Olas²⁰, Juan Manuel Mosquera Angarita²¹, Elena García- Guijarro²², Isabel Perales Fraile²³, Mayka Freire Dapena²⁴, Iván Pérez de Pedro²⁵, Luis Adrián Viteri Noël²⁶ and Eduardo Ramos ibáñez²⁷, ¹Hospital Clínic de Barcelona, Barcelona, Spain, ²Hospital Universitario La Paz, Madrid, Madrid, Spain, ³Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ⁴Hospital Clinic, Barcelona, Catalonia, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶Unidad de Reumatología, Hospital General de Medellín, Medellín, Colombia, Medellín, Colombia, ⁷Hospital Universitario Nacional de Colombia, Bogotá, Colombia, Bogotá, Colombia, ⁸Hospital Universitario Miguel Servet, Zaragoza, Spain, ⁹Alexandria Faculty of Medicine, Alexandria, Egypt, ¹⁰Sociedad Ecuatoriana de Reumatologia, Quito, Ecuador, ¹¹Universidad Pontificia Bolivariana, Medellin, Colombia, ¹²Hospital General Universitario Morales Meseguer, Murcia, Spain, ¹³ULS de Coimbra, Coimbra, Portugal, ¹⁴Hospital Metropolitano, Quito, Ecuador, ¹⁵Hospital St. Marina, Varna, Varna, Bulgaria, ¹⁶Hospital Universitario San Ignacio, Bogotá, Colombia, ¹⁷Hospital Universitario Parc Taulí, Barcelona, Spain, ¹⁸Hospital Universitario del Henares, Alcalá de Henares, Madrid, Spain, ¹⁹Asoreuma, Care for Kids, Bogota, Distrito Capital de Bogota, Colombia, ²⁰MCRIiR, Szpital Specjalistyczny im. J. Dietla w Krakowie, Cracow, Poland, ²¹Hospital Sant Joan de Déu, Barcelona, Spain, ²²Hospital Universitario Infanta Cristina, Madrid, Spain, ²³Hospital Universitario Infanta Sofía, Madrid, Spain, ²⁴Hospital Clínico Universitario de Santiago de Compostela, La Coruña, Spain, ²⁵Hospital Regional Universitario de Málaga, Málaga, Spain, ²⁶Hospital Universitario Ramón y Cajal, Madrid, Spain, ²⁷Capillary.io, Zaragoza, Aragon, Spain
Background/Purpose: Nailfold videocapillaroscopy (NVC) is a valuable non-invasive tool for assessing microvascular damage in autoimmune diseases. However, its application in idiopathic inflammatory myopathies (IIM) remains…
Abstract Number: 1108 • ACR Convergence 2025
Baseline Features, Immunosuppression, and Immune-Related Adverse Events in Patients with Pre-existing Rheumatic Disease and Cancer Requiring Immune Checkpoint Inhibitor Therapy
Laura Cappelli¹, Pankti Reid², Noha Abdel-Wahab³, Anne R. Bass⁴, Tawnie Braaten⁵, Cassandra Calabrese⁶, Nilasha Ghosh⁷, Tamiko Katsumoto⁸, Sang Kim⁹, Minna Kohler¹⁰, Alexa Meara¹¹, Namrata Singh¹², Jeffrey Sparks¹³, Maria Suarez-Almazor¹⁴, Ami Shah¹⁵ and Clifton Bingham¹⁶, ¹Johns Hopkins School of Medicine, Baltimore, MD, ²University of Chicago Medical Center, Chicago, IL, ³University of Texas MD Anderson Cancer Center, houston, TX, ⁴Hospital for Special Surgery, New York, NY, ⁵UNIVERSITY OF UTAH, Salt Lake City, UT, ⁶Cleveland Clinic Foundation, Cleveland Heights, OH, ⁷Hospital for Special Surgery, New York, NY, ⁸Division of Immunology and Rheumatology, Stanford University, Millbrae, CA, ⁹Yale University, Branford, CT, ¹⁰Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹¹The Ohio State University Wexner Medical Center, COLUMBUS, OH, ¹²University of Washington, Bellevue, WA, ¹³Brigham and Women's Hospital, Boston, MA, ¹⁴MD Anderson Cancer Center, Houston, TX, ¹⁵Johns Hopkins Rheumatology, Baltimore, MD, ¹⁶Johns Hopkins University, Baltimore, MD
Background/Purpose: Immune checkpoint inhibitors (ICIs) are effective therapies commonly used to treat malignancies but can cause flares or unrelated immune-related adverse events (irAEs) in patients…
Abstract Number: 0987 • ACR Convergence 2025
S-4321, a novel dual-cell bifunctional PD-1:FcγRIIb selective agonist antibody for autoimmune disease, maintains expression of PD-1 on target cells and enhances inhibitory receptor expression on T cells in vivo
Julia Manasson¹, Michael Cianci², Minasri Borah², Stephanie Grebinoski², Joshua Vitlip², Stephen Lutz², Ishan Sharma², Elliott Wittenberg², Allison Colthart², Samuel Perry², Maria Cecilia Ramello², Chelsea R. Parker Harp², Jyothsna Visweswaraiah², Ryan Peckner², Alex Pellerin², Heather Vital³, John Sundy⁴, Nathan Higginson-Scott², Kevin L. Otipoby² and Daniela Cipolletta², ¹Seismic Therapeutic, New York, NY, ²Seismic Therapeutic, Watertown, MA, ³Seismic Therapeutic, Lexington, MA, ⁴Seismic Therapeutic, Durham, NC
Background/Purpose: S-4321 is a novel antibody that agonizes the inhibitory PD-1 checkpoint receptor on T cells without competing for binding with its natural ligand, PD-L1,…
Abstract Number: 0922 • ACR Convergence 2025
Phenotypic and Transcriptomic Divergence in C3 Glomerular Mouse Models: Insights into Immune and Sex Correlates
Juan Liang¹ and kaiyuan zi², ¹Gempharmatech, Nanjing, Jiangsu, China, ²Gempharmatech, Nanjing, Jiangsu, Jiangsu, China
Background/Purpose: Complement component C3 plays a central role in the alternative pathway (AP) and is implicated in the pathogenesis of C3 glomerulopathy (C3G), a rare…
Abstract Number: 0698 • ACR Convergence 2025
A Retrospective Comparison of Transplant Outcomes with Different Induction Methods and Maintenance Prednisone in Systemic Sclerosis Patients
Lilit Grigoryan, Sumbal Wajid, Giovanni Faddoul and Swati Mehta, Albany medical center, Albany, NY
Background/Purpose: Systemic sclerosis (SSc) or scleroderma is a rare systemic autoimmune disease with multiple organ involvement. Renal involvement in SSc remains a significant concern, with…
Abstract Number: 0861 • ACR Convergence 2025
Identification of Anti-HDGFL1 as a Novel Autoantibody in Seronegative Idiopathic Inflammatory Myopathies
Xueting Yuan¹, Menghua Cai², Lu Gao², Chen Yu³, Jia Shi⁴, Yinghui Li², jiuliang Zhao¹, Dong Xu⁵, Chaojun Hu¹, Mengtao Li⁶, Xiaofeng Zeng⁷, jianmin Zhang² and Qian Wang⁶, ¹Peking Union Medical College Hospital (CAMS), Beijing, China (People's Republic), ²Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, China (People's Republic), ³Peking Union Medical College Hospital, Dong Cheng Qu, Beijing, China (People's Republic), ⁴University of Washington, Seattle, WA, ⁵Peking Union Medical College Hospital, Dong Cheng District, China (People's Republic), ⁶Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ⁷Peking Union Medical College Hospital Department of Rheumatology and Clinical Immunology, Beijing, Beijing, China (People's Republic)
Background/Purpose: Myositis-specific autoantibodies (MSAs) play a crucial role in diagnosing and classifying idiopathic inflammatory myopathies (IIMs). However, approximately 30% of seronegative IIM patients may be…
Abstract Number: 0431 • ACR Convergence 2025
Calprotectin Serum levels: a potential neutrophil activation biomarker to monitor treatment response in Rheumatoid Arthritis
Sangeeta Kumari¹, Eric meldrum¹, Josephine Stein¹, Tirza Bruurmijn¹, Robin de Jong², Katerina Pardali¹, Maarten Kraan¹, Renato Chirivi¹, Rogier Thurlings³ and Michael Nurmohamed², ¹Citryll BV, Oss, Netherlands, ²Reade, Amsterdam, Netherlands, ³Radboudumc, Nijmegen, Netherlands
Background/Purpose: Calprotectin is a protein highly expressed in myeloid cells and its elevated presence in blood, and the GI tract is associated with immune mediated…

1
2
3
…
101
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].